Search Results
Your search for ,New matches 16916 pages
Showing 13751 - 13800City of Hope’s New Chief Scientific Officer and Cancer Center Director Reflects on His Career Path and the Future of Cancer Care
City of Hope in Duarte, California, has named Steven T. Rosen, MD, as its first Provost and Chief Scientific Officer. Dr. Rosen will guide the scientific direction of the center’s medical research, treatment, and education. He will also assume directorship of the comprehensive cancer institute,...
Cancer Treatment Centers Names Sr. Vice President, Patient Care Services
Cancer Treatment Centers of America in Philadelphia has announced they have recently hired Nancy G. Hesse, MSN, RN, as the hospital’s Senior Vice President of Patient Care Services. In her new role, Ms. Hesse will work on several key initiatives for her team related to engagement, communication,...
Dana-Farber Receives $900,000 Grant to Research Ovarian Cancer
The Ovarian Cancer Research Foundation has awarded researchers at Dana-Farber Cancer Institute a $900,000 grant to test new combinations of targeted drugs against the disease. Ursula Matulonis, MD, Director of the Gynecological Cancer Treatment Center in the Susan F. Smith Center for Women’s...
Advanced Practitioner Society for Hematology and Oncology (APSHO) Welcoming Members
The Advanced Practitioner Society for Hematology and Oncology (APSHO) is issuing a call for members to oncology nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, and pharmacists. The Society was launched recently during JADPRO Live, a meeting of the...
Cancer Pain: The Humbling Reality
As a medical oncologist and palliative care physician, I’ve had the privilege of caring for cancer patients and delivering primary palliative care and symptom control, as well as the chance to care for patients especially referred for complex pain and symptom problems (in secondary and even...
Overdiagnosis of Breast Cancer: New Research Directions
Currently, one of the most challenging problems in oncology is to accurately predict whether neoplastic lesions detected by screening tests will progress. The focus on developing ever-more sensitive cancer screening tests has produced the clinical dilemma of overdiagnosis. Overdiagnosis occurs when ...
Flaws in CNBSS Are Vast, Impact on Screening Recommendations Is Nil
The recent report from the Canadian National Breast Screening Study (CNBSS)—published in BMJ and reviewed in The ASCO Post, early release online—concluded that annual mammography in women aged 40 to 59 does not result in a reduction in mortality from breast cancer beyond that of physical...
2014 Oncology Meetings
MARCH 31st Annual Miami Breast Cancer Conference®March 6-9 • Miami Beach, FloridaFor more information: www.gotoper.com/conferences/mbcc/meetings/31st-Annual-Miami-Breast-Cancer-Conference Hematology and Medical Oncology Board Review: Contemporary Practice from Memorial Sloan-Kettering Cancer...
APSHO: New Society for Advanced Practitioners
The Advanced Practitioner Society for Hematology and Oncology (APSHO) was launched during JADPRO Live. The Society is focused on meeting the unique educational and professional needs of this group of health-care professionals (nurse practioners, physician assistants, clinical nurse specialists,...
Leaders of ASCO, ASH, ASTRO, and NCCN Embrace Collaboration With Advanced Practitioners
Nearly 250 advanced practitioners assembled at the first annual JADPRO Live educational symposium in St. Petersburg, Florida, hosted by the Journal of the Advanced Practitioner in Oncology (JADPRO). Leaders from four prominent oncology organizations championed collaborative practice as not only...
Expert Point of View: Jennifer R. Brown, MD, PhD
Commenting on the CLL 11 trial in chronic lymphocytic leukemia (CLL), Jennifer R. Brown, MD, PhD, Director of the CLL Center at Dana-Farber Cancer Institute, Boston, said she agreed with first author Valentin Goede, MD, that in this study, replacing rituximab (Rituxan) with obinutuzumab (Gazyva) in ...
Encouraging Early Results With Novel Agents in CLL
Two novel agents have shown promising activity in chronic lymphocytic leukemia (CLL), including poor-risk patients: the Bcl-2 inhibitor ABT-199 and the small-molecule PI3K inhibitor IPI-145. Both drugs achieved excellent response rates in heavily pretreated relapsed/refractory patients including...
FDA Approves Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
The U.S. Food and Drug Administration (FDA) has expanded the approved use of ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one previous therapy. Ibrutinib, an oral Bruton’s tyrosine kinase inhibitor, was previously granted...
Haploidentical Stem Cell Transplantation Producing Good Outcomes, Expanding Transplant Pool
HLA-haploidentical hematopoietic stem cell transplantation can be performed safely, yield good outcomes, and greatly expand the number of patients with hematologic malignancies who can be treated with stem cell transplant, studies presented at the 2013 American Society of Hematology (ASH) Annual...
Updated Information on Clinical Trials
Your patients can learn about clinical trials in a variety of ways at www.cancer.net/clinicaltrials. The articles available explain what clinical trials are, how they are used to learn more about cancer care, and how they are conducted. In addition, your patients can read a new article explaining...
Cancer.Net Expands Its Social Media Presence With Launch of Blog
In an effort to continue to bring patients and those who care about and for them the most timely, comprehensive cancer information, ASCO’s patient education website, Cancer.Net, has added a new interactive resource—the Cancer.Net Blog (www.cancer.net/blog). “We decided that a blog made sense for...
Cancer Progress in Jeopardy: Stories From the Front Lines
ASCO is exploring what is happening on the front lines in the laboratory and the clinic due to the shrinking federal funding for cancer research and clinical trials with a series of stories about oncologists. The series is posted on ASCO.org (www.asco.org/nihfunding). In the first article, Robert...
Expert Point of View: Carlos L. Arteaga, MD
Commenting on the results of the HOPE Study presented at the 2013 San Antonio Breast Cancer Symposium, Carlos L. Arteaga, MD, said, “We all know that this is the right thing to do. This important study provides us with new guidelines and a structure so that patients find it easier to follow the...
Exercise Program Reduces Aromatase Inhibitor–Associated Joint Pain
Amid studies of novel targeted therapies, genetic analyses of tumors, and new ways to approach the treatment of breast cancer, a low-tech study presented at the 2013 San Antonio Breast Cancer Symposium found that a yearlong exercise program reduced joint pain associated with aromatase inhibitors in ...
Innovative I-SPY 2 Trial Yields First Results in Triple-Negative Breast Cancer
An innovative approach to streamlining the testing of novel agents in breast cancer has yielded some of its first results, which were reported at the 2013 San Antonio Breast Cancer Symposium.1 Adaptive Trial Design The veliparib/carboplatin plus standard neoadjuvant therapy regimen is currently...
HER2-Positive Breast Cancer Patients With Small Tumors Benefit From Low-Toxicity Regimen
There may be a benefit for treating small HER2-positive tumors—a breast cancer subset for whom treatment recommendations have not been established but for whom there is still risk of recurrence—and this can be done with little toxicity, according to a multicenter study presented at the 2013 San...
GI Symposium Presentations Include Important Updates in Treatment and Prognosis of Pancreatic and Colorectal Cancers
More than 650 studies were presented at the 2014 Gastrointestinal Cancers Symposium, which attracted a multidisciplinary group of more than 3,500 medical, surgical, and radiation oncologists and gastroenterologists. The following briefs highlight a handful of noteworthy studies from the meeting....
U.S. Government Accountability Office Issues Report on Drug Shortages
The U.S. Government Accountability Office (GAO) recently issued a report evaluating drug shortages and the associated public health threats, including prolonged duration of a disease, permanent injury, and death.1 This report follows a recommendation by GAO in 2011 that the U.S. Food and Drug...
Capecitabine Acceptable in Neoadjuvant Rectal Cancer Setting
As neoadjuvant therapy for rectal cancer, infusional fluorouracil (5-FU) and oral capecitabine achieve similar outcomes, and the addition of oxaliplatin confers no additional benefit, according to the mature results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) R-04 trial,...
Expert Point of View: Josep M. Llovet, MD
Josep M. Llovet, MD, Professor of Medicine at Mount Sinai Hospital, New York, commented on the findings reported by Faivre et al for The ASCO Post. “This is the first time a TGF-β inhibitor has been clinically tested in hepatocellular carcinoma, and the drug has a good safety profile. But this is a ...
Expert Point of View: Michael J. Morris, MD, and Maha H. Hussain, MD, FACP, FASCO
Commenting on the ALSYMPCA follow-up study presented at the Genitourinary Cancers Symposium, Michael J. Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, New York, said that radium-223 was a very effective and safe drug, but its actual target and mechanism of action are...
Sequencing Sorafenib and Sunitinib in Either Order Does Not Affect Survival in Metastatic Renal Cell Carcinoma
The explosion of new therapies for metastatic renal cell carcinoma is a welcome advance, but studies have not yet defined optimal sequencing of the newer therapies. According to the phase III SWITCH trial, it matters little whether therapy for metastatic renal cell carcinoma begins with sorafenib...
Cytoreductive Nephrectomy Improves Survival in Metastatic Renal Cell Carcinoma Patients With Longer Life Expectancy
Prior to the advent of targeted therapy, cytoreductive nephrectomy was associated with a 6-month improvement in overall survival in patients with metastatic renal cell carcinoma. With new and better targeted therapies for the disease, the appropriate use of cytoreductive nephrectomy has been...
Congress Agrees on Repeal of Sustainable Growth Rate
The U.S. Congress recently did something rarely seen on Capitol Hill: Leaders from both sides of the aisle agreed on a piece of legislation. On February 6, 2014, the House Energy and Commerce and Ways and Means Committees and the Senate Finance Committee announced its agreement on a bill—the SGR...
The Future of Biomedical Research
In January, Congress approved a $1 trillion appropriations bill for the rest of fiscal year 2014. While the new bill includes $29.9 billion for the National Institutes of Health (NIH)—$1 billion above FY2013 levels after sequestration—including $4.9 billion for the National Cancer Institute (NCI),...
Expert Point of View: Charles Ryan, MD
Charles Ryan, MD, moderator of the press conference at the Genitourinary Cancers Symposium where the PREVAIL trial data were discussed, emphasized that this study breaks new ground for enzalutamide (Xtandi) in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. “The...
Task Force Recommends Against Beta-Carotene or Vitamin E Supplements for Primary Cancer Prevention
The U.S. Preventive Services Task Force (USPSTF) recommends against the use of beta-carotene or vitamin E supplementation for the primary prevention of cancer or cardiovascular disease, according to an updated recommendation statement published in the Annals of Internal Medicine. “The USPSTF found...
‘Epidemic of Diagnosis’ of Thyroid Cancer Is Most Acute for Women
The epidemiology of the increased incidence of thyroid cancer, which has nearly tripled since 1975, “suggests that it is not an epidemic of disease but rather an epidemic of diagnosis,” Louise Davies, MD, MS, and H. Gilbert Welch, MD, MPH, concluded after analyzing trends in patients diagnosed with ...
For Metastatic Colorectal Cancer, Bevacizumab Is More Commonly Included Than Anti-EGFR Antibody Therapies
Analysis of a large cohort of patients with metastatic colorectal cancer who received chemotherapy at academic, private, and community-based oncology practices using the same chemotherapy order entry system showed that “bevacizumab has been more consistently integrated into treatment regimens than...
Dermatologists Defend Mohs Surgery as Effective and Cost-Efficient With Low Rate of Recurrence
The headline, “Patients’ Costs Skyrocket, Specialists’ Incomes Soar,” aptly encapsulates the theme of a recent article in The New York Times,1 part of a series entitled, “Paying Till It Hurts.” “Oncologists benefit from the ability to mark up (and profit from) each dose of chemotherapy they...
2014 Oncology Meetings
MARCH Society of Surgical Oncology Annual Cancer Symposium March 13 - 16 • Phoenix, ArizonaFor more information: www.surgonc.org 24th Annual Interdisciplinary Breast Cancer ConferenceMarch 15-19 • Las Vegas, NevadaFor more information: www.breastcare.org/ 9th European Breast Cancer ConferenceMarch ...
Cognitive-Behavioral Therapy Plus Hypnosis Controls Fatigue in Breast Cancer Patients Receiving Radiotherapy
In a study reported in the Journal of Clinical Oncology,1 Guy H. Montgomery, PhD, Icahn School of Medicine at Mount Sinai, New York, and colleagues found that an intervention consisting of cognitive-behavioral therapy plus hypnosis produced better control of fatigue than supportive meetings with...
The Ketogenic Diet in Cancer Control
Ketogenic (or very-low-carbohydrate) diets have been employed since the 1920s as nonpharmacologic therapies for epilepsy and, in some instances, have obviated the need for medication for that disease. Since the 1960s, the ketogenic diet has become better known as a means of managing obesity. This...
Telemedicine: Efficiency in Cancer Screening and Outreach
As defined by the U.S. Health Resources and Services Administration teleheath is “the use of electronic information and telecommunications technologies to support long-distance clinical health care, patient and professional health-related education, public health, and health administration.” It has ...
Telephone Education and Counseling Effective in Programs Targeting Familial/Genetic Cancer Risk Screening
Two studies recently reported in the Journal of Clinical Oncology indicate that telephone-based education or counseling initiatives can be successful in educating individuals at familial or genetic risk of cancer and in inducing these at-risk individuals to undergo recommended screening. In the...
How Decoding the Genomes of Exceptional Responders Is Leading to More Effective Treatment for All Patients With Cancer
In 2012, David B. Solit, MD, Geoffrey Beene Chair and Director of the Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, and his colleagues published the results of a phase II study1 of 45 patients with advanced bladder cancer. The purpose of the clinical...
President Obama’s FY 2015 Budget Proposal
[On March 4, 2014], President Obama released his proposed budget for fiscal year 2015. Among several cost-cutting measures designed to preserve Medicare solvency is a proposal to reduce reimbursement for life-sustaining cancer drugs. Currently, reimbursement to physicians for “Part B” drugs is...
Neuro-Oncology Community Convenes in Workshop to Advance Imaging-Related Endpoints in Clinical Trials
Leaders from key cross-sections of the neuro-oncology community came together at a recent Brain Tumor Clinical Trial Endpoints Workshop to confront a critical challenge in developing and testing treatments for glioblastoma multiforme. Participants were able to adjourn the workshop with the...
Affordable Care Act to Cover Chemoprevention for Women at High Risk for Breast Cancer
On January 9, 2014, Kathleen Sebelius, Secretary of the Department of Health and Human Services, announced that under the Patient Protection and Affordable Care Act, women at increased risk of breast cancer will be entitled to preventive medications without incurring out-of-pocket costs (with the...
ASCO Addresses Changes in Medicare for 2014
Medicare patients make up 61% of new cancer cases in the United States, and as the population ages, that proportion is expected to rise to 70% by 2030. Over the past decade, the oncology community has been financially challenged by alterations in the Medicare payment system. To address the changes...
Antitumor Activity of Poly-IC and Anti–PD-L1 Monoclonal Antibody
Epitope-based vaccines that induce CD8-positive T-cell responses to tumor-associated antigens are being investigated in the treatment of several types of cancer. In a study reported in Clinical Cancer Research, Nagato and colleagues showed that combined immunotherapy with polyinosinic-polycytidylic ...
National Program to Screen Ashkenazi Women in Israel for BRCA Mutations Is Being Explored
Citing a World Health Organization report that lists Israel as having one of the highest rates of breast cancer in the world, The New York Times reported on a proposed screening program to identify women with BRCA1 and BRCA2 mutations.1 “A number of influential geneticists and cancer doctors from...
Stay Up-to-Date on New Patient Materials From Cancer.Net
Encourage your patients to use social media to stay-up-to-date with the new resources available on Cancer.Net. It is easier than ever for patients to get the latest cancer information on their computer or mobile device by subscribing to the Cancer.Net Blog at www.cancer.net/blog, or on...
ASCO’s Membership Grows to Nearly 35,000
ASCO has much to celebrate this year—namely, the Society’s 50th Anniversary. This occasion brings with it many other notable milestones. 2014 is a prime time to reflect on the remarkable growth of ASCO, from seven founders and 51 physicians at its first Annual Meeting to nearly 35,000 members...
ASCO Holds Leadership Summit to Address Value in Cancer Care, Cost of Cancer Drugs and Technologies
ASCO convened a leadership summit in late January with pharmaceutical representatives, insurance payers, patient advocates, and physicians to initiate a dialogue on the challenge of defining value in cancer care. This meeting was held amid growing concerns about the sustainability of continued...
